HPV infection

Details numerous safety concerns with the Gardsail vaccination, which is currently offered for free to young girls in Canada, mostly between the ages of 9-12, as a protection against some forms of the human papillomavirus (HPV) which can cause cervical cancer. Summarizes some of the major questions and concerns that the authors felt needed to be addressed before there was a full-scale roll-out of an HPV vaccination program.

Discusses specific elements of the analytic framework for immunization programs in Canada. Makes recommendations about the use of HPV vaccine. Comments on important research gaps for the optimal use of this vaccine in Canada.

Report on the proceedings of an invitational HPV Vaccine Research Priorities Workshop on November 17-18, 2005, in Quebec City hosted by The Public Health Agency of Canada (PHAC) and the Canadian Association for Immunization Research and Evaluation (CAIRE), in partnership with the Canadian Institutes of Health Research (CIHR) Institute of Infection and Immunity and the Institute of Cancer Research, held. The workshop was attended by 53 Canadian and international HPV experts and researchers from the areas of vaccines, cancer, and sexually transmitted infections. The purpose of the meeting was to examine the current Canadian and international status of HPV vaccine research and develop national research priorities before the vaccines become approved for use in Canada.

Summarize some of the major questions and concerns to be addressed before there is a full-scale roll-out of an HPV vaccination program.

Submitted to the Globe and Mail January 31, 2008 discussing misinformation published in the newspaer about  the HPV vaccine, Gardasil.

Gives basic information about Human Papilloma Virus (HPV), a common sexually transmitted infection (STI). Includes information about testing and treatment.

Outlines the main concerns that the Fédération du Québec pour le planning des naissances (FQPN), along with many women’s, teachers’, nurses’ and youth organizations, have about the vaccination program that was introduced in Quebec against the human papillomavirus (HPV) in hopes of reducing rates of cervical cancer.

Translated and adapted by Women and Health Protection and the Canadian Women’s Health Network.

In June 2007, the Canadian Women's Health Network published the policy paper, "HPV, Vaccines, and Gender: Policy Considerations," to raise questions and concerns about plans to begin mass vaccination programs against infections with some types of the human papilloma virus (HPV) among schoolgirls in Canada. This is a reflection piece written a year later.

Addresses the questions and concerns regarding the new human papillomavirus (HPV) vaccine, Gardasil.

Discusses the reasons to be weary of the new humanpapillomavirus (HPV) vaccine, Gardasil and how the number one weapon against cervical cancer is still Pap smear screening.